AACE Podcasts

Episode 71: 2025 Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease Overview

Join endocrine expert Dr. David Lieb as he moderates a discussion with Dr. Karl Nadolsky, Chair of the AACE Obesity Algorithm, and Dr. Timothy Garvey, Vice Chair, as they review the 2025 AACE Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease and highlight key updates since 2016. The experts discuss advances in pharmacotherapy, the evolution of complication-centric and person-centered care, and strategies to reduce weight bias in clinical practice. They also share guidance on individualizing therapy and look ahead to the future of obesity medications as new treatments emerge.

Episode 70: 2025 Algorithm for Management of Adults with Dyslipidemia Update Overview

Join endocrine expert Dr. David Lieb as he moderates a discussion with Dr. Shailendra Patel, Chair of the 2025 AACE Dyslipidemia Algorithm; Dr. Maria Belalcazar, Vice Chair; and Dr. Robert Hegele, Author and Representative of the Canadian Cardiovascular Society, about the 2025 Updated Algorithm for Management of Adults with Dyslipidemia. This episode covers: * The rationale behind updating the algorithm and how it aligns with the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia * Key updates from the 2020 algorithm, including expanded guidance on hypertriglyceridemia and lipid management in special populations * Practical strategies for integrating the algorithm into everyday clinical practice and medical education with an emphasis on patient-centered care, shared decision making, and health equity * Emerging therapies on the horizon and priority areas for future research   Tune in to hear expert insights on how this updated, evidence-based resource can support better clinical decision making and improve patient outcomes.

Episode 69: Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care: A Quality Improvement Project

Join Dr. Cecilia Lansang, Associate Editor of Endocrine Practice, Professor of Medicine, and Director of Endocrinology at Cleveland Clinic, as she speaks with Dr. Kristen Flint, Interim Director of Quality and Safety for Endocrinology at Massachusetts General Hospital, Attending Endocrinologist at MGH, and Instructor at Harvard Medical School, about her team’s quality improvement project, “Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care.”   This episode covers: * Strategies for implementing quality improvement interventions in a large academic diabetes specialty clinic * Key interventions that increased CGM utilization, including targeted provider education, workflow optimization, and patient outreach * Lessons for advancing equitable implementation and sustaining quality improvement over time   Tune in for practical insights on bridging policy changes and clinical practice to improve CGM access for Medicare patients. Read the full article in the August 2025 issue of Endocrine Practice here [https://secure-web.cisco.com/1t19WSnGcRixOffRSjgXK_iHjHnUeDdb4FCToB1FnOFMzSo0trIxgv0AyrVMxinC6681W9-mVCvCQ8nCZ9wWG46W1ezIVhiH-13LI_slyPZ9OSMtiB3Cjxla6dYYAMMAyV1aMf-lAL16zYKMwBpfuzoIq4jo19_lLII6WnKQq2pyctHSUBqinuFoBIbiMpKJDLNtR81DfcCWgMUjImqNiC-ItpGUO9SDrOnmE6dwovtGTTnPSHYce-N5yVB7pKfAa8X1digssHRE1vjus9Df2bkvTqhzj0M11lbY1iaVHNDTDlg-vgSEMIDzmOHfidiAG/https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1530891X25001053].

Episode 68: Impulse Control Disorders in Patients with Hyperprolactinemia on Dopamine Agonist Therapy

Join Elizabeth M. Bauer, MD, FACP, FACE, Dipl ABOM, as she interviews Nicholas A. Tritos, MD, DSc, Professor of Clinical Medicine at Harvard Medical School and faculty of the Neuroendocrine Unit/Neuroendocrine and Pituitary Tumor Clinical Center at Massachusetts General Hospital, about his Endocrine Practice article, Impulse Control Disorders in Patients with Hyperprolactinemia on Dopamine Agonist Therapy – How Concerned Should We Be? The conversation explores the prevalence and risk factors for impulse control disorders, underlying biological mechanisms, clinical screening strategies, and approaches to patient counseling and management. Read the full article in the July 2025 issue of Endocrine Practice here: https://doi.org/10.1016/j.eprac.2025.04.018 [https://secure-web.cisco.com/1i9sEfZWRRjtQhWFPuDSmLgKBu_wG3aeX0R690OrkUS7RbKoaEKkiU-7dfP7muKNYNgKe1qZ6jOfXcR_NkU_HCWkCt3cRziHZCMHjmv7E2oDgToNjA0CrKqLrirUWHbxrwpoQa3poUQNk_d3yzff-oPbitqBi_qVtGiuZpSjy7t3n8RUaHC_-WX_5HlhCHSgkEpfwYzJ6_HLOi-ZVAtgQ5t5cY5iLsFB5kMitMA2reOej3quIyaLOEFi741fNFXEJR3bwkLsqzRCjaoXo1M7vPgaZa8QGtnLq0VwAfaK1s74gWgWH7mBAFddtUryMdz1T/https%3A%2F%2Fdoi.org%2F10.1016%2Fj.eprac.2025.04.018]

Episode 67: Obstructive Sleep Apnea – Screening and Treatment Updates

Join leading experts Fariha Abbasi-Feinberg, MD, FAASM, Medical Director of Sleep Medicine at Millennium Physician Group and President Elect for the American Academy of Sleep Medicine; Inderpreet K. Madahar, MD, MBBS, Assistant Professor of Endocrinology, Diabetes, and Metabolism at Corewell Health; and Sarah Nadeem, MD, FACE, Assistant Professor, Section of Endocrinology, Diabetes, and Metabolism at Baylor College of Medicine, Houston, TX, as they discuss the complex relationship between obstructive and central sleep apnea and metabolic disorders such as obesity and type 2 diabetes. Key topics include: * Who should be screened for sleep apnea and the recommended screening tools * First-line and adjunctive therapies for management * The evolving role of multidisciplinary care * How clinical practice is shifting with the recent FDA label expansion of tirzepatide (Zepbound®) * When tirzepatide may be considered alongside or in place of CPAP, APAP, and BiPAP therapies Tune in for practical insights to better identify, manage, and support patients at risk. This episode is made possible through a sponsorship from Lilly.